Nexentis unit MitoCareX completes broad structural analysis of human SLC transport proteins
PUBT · 2d ago
Share
Listen to the news
- Nexentis subsidiary MitoCareX completed a broad structural analysis of human SLC transport proteins to expand its small-molecule discovery engine.
- Work extends MITOLINE, previously used for mitochondrial SLC25 carriers, to identify non-SLC25 targets compatible with its modeling ruleset.
- MitoCareX plans to use MITOLINE-derived 3D models in virtual screening for selected non-mitochondrial SLC targets.
- Move could widen MitoCareX’s addressable transporter set for hard-to-treat cancers and inflammatory metabolic diseases.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexentis Technologies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606170732PRIMZONEFULLFEED9748454) on June 17, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved